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Lmortality at 30 days, with one death in a patient with functional MR after 5.8 years and
a degenerative MR patient after 3.2 years. There were no strokes with an average
follow-up of 2.41.8 years. There were sustained improvements in New York Heart
Association class (from 2.8  0.6 to 1.6  0.5, p <0.001) and MR grade (from 3.5 
0.9 to 0.4  0.5, p <0.001) at follow-up.
Conclusions: In this large single center experience, no patient required urgent cardiac
surgery for failed MitraClip procedure. Mitral valve repair rate in patients with
degenerative MR was high, and surgical options were preserved in the remaining
patients. Overall, cardiac surgical outcomes were excellent.
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Background: In primary or degenerative mitral regurgitation (DMR), the mitral valve
(MV) leaﬂets are structurally abnormal. The MitraClip device is the only percutaneous
leaﬂet-based therapy evaluated by both randomized and registry-based studies
utilizing core lab evaluation of patients with moderate to severe or severe ( 3+)
DMR. Functional MR has been separately and previously evaluated.
Methods: One-year data from the EVEREST II studies were analyzed for 509 patients
with severe baseline DMR, including 447 treated with MitraClip and 62 who
underwent a ﬁrst MV surgery.
Results: MV leaﬂet pathologies of prolapse and ﬂail were well-represented.
Compared to surgical candidates, high-risk DMR patients had STS mortality risk
scores of 12%, or surgeon assessment of excessive risk based on pre-speciﬁed
factors. They were older, more frequently had serious baseline co-morbidities, and
had more severe functional impairment than DMR patients in the RCT (Table 1).
Implant rates were consistently high across MitraClip DMR cohorts. Safety
outcomes reﬂected patient risk status. Lower-risk DMR patients who underwent
MV surgery had more complete MR reduction and greater improvement in LV
volumes than did lower-risk DMR patients who received MitraClip. Despite their
burden of co-morbidities, a large proportion of high-risk DMR patients who
received MitraClip achieved and maintained MR reduction to 2+ or less and did
not undergo MV surgery.Table 1. Baseline characteristics and outcomes* in EVEREST II High Risk (a)














Age 82  9 yrs 75  12 yrs 67  13 yrs 63  13 yrs
Coronary Artery Disease 74% 40% 37% 32%
Previous cardiovascular
surgery
52% 13% 12% 10%
Atrial Fibrillation 72% 53% 30% 29%
STS mortality risk score 13.6  8.4% n/a 3.7 3.1% 3.1  2.9%
LV Ejection Fraction 60  10% 60  7% 64  6% 65  6%
Anterior/Bileaﬂet Flail/
Prolapse
47% 39% 45% 35%
Posterior Flail/Prolapse 42% 50% 52% 61%
Mortality at 30 days 7.0% 1.1% 1.5% 3.2%
Major Adverse Events at 30
days
17.2% 10.2% 13.8% 51.6%
Freedom from MR >2+ at
1 year in surviving patients
86% 79% 84% 100%
Improvement in LVEDV at 1
year
-20  23 ml -13  22 ml -28  29 ml -48  36 ml
NYHA Class III/IV: Baseline
/ 1 year
79%/ 13% 52%/ 7% 41%/ 2% 39%/ 4%
Improvement in SF-36 PCS
at 1 year
5.9  8.9 6.2  8.9 5.2  9.8 4.2  10.6
*Echo data pending ﬁnal core lab review; MAE data pending ﬁnal CEC adjudication
JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: In the EVEREST II DMR experience, the safety proﬁle of the MitraClip
has been demonstrated in both high risk and lower risk cohorts. While surgery was
more effective in lower risk DMR patients, MitraClip provides meaningful
improvements of LV volumes, NYHA Class and Quality of Life in all DMR patient
cohorts, demonstrating that the MitraClip is an important therapeutic option for select
DMR patients.
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Background: Following CE approval in 2008, percutaneous mitral valve repair with
the MitraClip system (Abbott) has entered clinical practice in Europe, where it is
predominantly used to treat patients (pts) at high surgical risk. We sought to assess,
and elucidate the interrelation of, baseline echocardiographic variables predictive of
acute procedural failure in such pts.
Methods: The ﬁrst 300 consecutive pts (75  9 years, 190 men [63%]) who
underwent MitraClip therapy for grade 3+/4+ mitral regurgitation (MR) at our insti-
tution comprised the study cohort. All pts were adjudicated by heart team consensus as
not amenable to surgery. Procedural failure, deﬁned as discharge MR 3+, was
encountered in 32 patients (10.7%), with 11 aborted procedures (no clip implanted)
and 21 clip failures (MR 3+ despite clip implantation).
Results: Exact logistic regression analysis identiﬁed effective regurgitant oriﬁce area
(EROA), mitral valve oriﬁce area (MVOA), mean transmitral pressure gradient (TPG),
and MR severity (not quantiﬁed via EROA) as predictive of failure. Classiﬁcation tree
analysis (Figure) revealed EROA as the variable with highest discriminatory power,
followed by MVOA, TPG and MR severity. The highest incidence of clip failures
occurred in pts with EROA >0.71cm2, highest incidence of aborted procedures in pts
with MVOA 3.0cm2 and TPG 4mmHg.SConclusions: Baseline echocardiographic variables differentially impact the proce-
dural outcome of MitraClip therapy. Classiﬁcation tree analysis clariﬁes their inter-
relationship and may help to reduce the procedural failure rate.
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Background: Impaired renal function (RF) is strongly associated with poor outcome
in patients (pts) with chronic heart failure (HF). We sought to assess the acute effect of
MitraClip therapy (MC) on RF and its impact on mortality and HF rehospitalization.
Methods: In a retrospective analysis of 306 surgical high-risk pts (74.4  8.7 years,
197 men [64.4%]) with grade 3+ mitral regurgitation (MR) treated by MC, we
calculated glomerular ﬁltration rate (GFR) at baseline (BL) and discharge from
creatinine levels (CKD-EPI formula). GFR was converted into the 5 Kidney Disease
Outcomes Quality Initiative (KDOQI) stages. Pts were followed for 16  11 (range,
0.3-41) months.
Results: MC acutely improved RF (DKDOQI <0) in 82 pts (27%) and worsened RF
(DKDOQI >0) in 31 pts (10%), with no change in 63% of pts. Overall, survival wasacts/ORAL/Percutaneous Treatment of Mitral Valve Disease B29





Ssigniﬁcantly different in the 3 groups (Figure). Compared with pts in whom MC
caused no change in RF, there was a trend toward improved survival out to 2 years in
pts with acutely improved RF and signiﬁcantly poorer survival in pts with worsened
RF. Multivariate Cox regression analysis revealed DKDOQI – next to MC failure,
presence of dilated cardiomyopathy, and peripheral arterial disease – as independently
predictive of mortality (hazard ratios vs. pts with worsened RF: improved RF 0.31
[p¼0.0005], unchanged RF 0.46 [p¼0.006]). DKDOQI did not impact the rate of
rehospitalization for HF.
Conclusions: MC in surgical high-risk pts acutely improves RF in about one quarter
of pts. These pts exhibit improved survival compared to those without acute change





Freedom from death at 1 year 74%
Freedom from MR >2+ at 1 year in surviving patients 84%
Freedom from mitral valve surgery at 1 year 97%
Improvement in LVEDV at 1 year -15  28 ml
% patients with NYHA Class III/IV: Baseline/ 1 year 87%/ 19%
Improvement in SF-36 QoL Physical Component
Summary at 1 year
4.1  9.3 points
Improvement in SF-36 QoL Mental Component Summary
at 1 year
3.4  11.6 points
Rate of hospitalizations for HF
(1-year pre-procedure/ 1-year post-procedure)
0.80/ 0.41TCT-92
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Background: Transcatheter mitral valve-in-valve / valve-in-ring implantation is an
emerging therapeutic alternative for patients with failed mitral valves after surgical
intervention and may obviate the need for a redo operation. We aimed to evaluate the
clinical results of this technique using a large worldwide registry.
Methods: The registry included 134 patients with degenerated mitral valves after
surgical intervention (12.7% ring only, median of 9 years post procedure) from 22
centers. Mean age 74.3  11 years; 64.4% female (STS score 16.1  13.1%). The
mode of failure was regurgitation (n¼64, 47.8%), stenosis (n¼34, 25.4%), and
combined stenosis and regurgitation (n¼36, 26.9%).
Results: Transcatheter Edwards SAPIEN (Edwards Lifesciences, Irvine, CA)
implantation was performed in all cases (23 mm in 15.7%, 26 mm in 58.2%, and 29
mm in 26.1%). Procedural access was transapical in 117 cases (87.3%); transseptal in
12 (9%), and through the left atrium via right mini-thoracotomy in 5 (3.7%). Twenty
combined procedures (14.9%) included aortic valve-in-valves, aortic valve replace-
ment, tricuspid valve-in-ring implantation, and paravalvular leak closure. Device
malposition appeared in 6 cases (4.5% of cases) and post implantation valvuloplasty
was utilized in 8%. Post-procedure, mitral valve area was 2  0.6 cm2, valve
maximum / mean gradients were 13  6.3 mmHg / 6.4  3, respectively, and
signiﬁcant mitral regurgitation (+2) was observed in 5.2% of patients. Median length
of hospital stay was 7 days. At 30-day follow-up, all-cause mortality was 8.2%, 1.5%
of patients had stroke and 79.2% were at New York Heart Association functional
class I/II.
Conclusions: Mitral valve-in-valve/ valve-in-ring implantations, performed in
extremely high-risk patients, were clinically effective in most patients with degener-
ative mitral valves after surgery. The safety and efﬁcacy of this approach will be
further examined.B30 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-93
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Background: Elderly patients with severe mitral regurgitation (MR) often present
with multiple serious co-morbidities including heart failure (HF), and therefore are
not considered candidates for mitral valve surgery due to high risk of surgical
mortality and morbidity. These patients have limited options as no medical therapy
is directed speciﬁcally at reducing MR. The MitraClip system has emerged
as an important non-surgical treatment option. Results in the high risk octoge-
narian cohort treated with MitraClip in the EVEREST II studies have not been
presented.
Methods: High risk patients age 80 years had 3+/4+ MR at baseline and were
deemed high risk for surgery as predicted by STS mortality risk score of 12%, or
surgeon assessment based on pre-speciﬁed factors. Echocardiograms were evaluated
by an independent core lab. Clinical outcomes at 1 year including change in left
ventricular (LV) volume, NYHA class, quality of life (QoL), and hospitalizations for
HF were analyzed.
Results: A total of 146 high risk octogenarians (mean age 85 yrs) underwent the
MitraClip procedure. Baseline co-morbidities included CAD (80%), prior CABG
(47%) and moderate to severe renal disease (33%). Baseline LVEF was 5214%.
Predicted mortality (STS risk score) was 158%. Actual 30-day mortality was 7.5%.
Despite advanced age and burden of co-morbidities, 84% of octogenarians achieved
MR reduction to 2+ post-MitraClip and 90% were discharged home. At 1 year,
octogenarians showed improvements from baseline in clinical and functional measures
(Table 1).Conclusions: In high risk octogenarians, the MitraClip procedure resulted in mean-
ingful improvements in MR severity, LV volumes and QoL. Percutaneous reduction
of MR with the MitraClip is a therapeutic option for high risk elderly patients with
multiple co-morbidities who are not candidates for surgery.j TCT Abstracts/ORAL/Percutaneous Treatment of Mitral Valve Disease
